Another thing that has caught my attention so far:
Diagnostics growth: pre-surgical brain mapping of speech and motor cortices
Our addressable market estimates for pre-surgical brain mapping are conservative. Here is why:
We only include the US and the EEA markets, although Nexstim holds regulatory approvals across various countries in APAC, the Middle East, Oceania and Latin America, serving these markets through partners and distributors.
We also restrict the universe of potential clients to Tier-1 hospitals and clinics (~1.2k), on the basis that Nexstim sells premium systems to premium clients.
The resulting € 72-84m annual addressable market should therefore be read as a floor.
I’m not going to speculate on how much larger that market could be, but the level they use is underlined as being their estimated minimum level.